Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome

Creative Commons License

ŞÜKÜR Y. E., ÖZMEN B., Ozdemir E. D., SEVAL M. M., Kalafat E., SÖNMEZER M., ...Daha Fazla

REPRODUCTIVE BIOMEDICINE ONLINE, cilt.34, sa.1, ss.5-10, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.rbmo.2016.10.004
  • Dergi Adı: REPRODUCTIVE BIOMEDICINE ONLINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.5-10
  • Anahtar Kelimeler: GnRH agonist trigger, GnRH antagonist, intracytoplasmic sperm injection, leuprolide, triptorelin, HUMAN CHORIONIC-GONADOTROPIN, IN-VITRO FERTILIZATION, HORMONE AGONIST, FOLLICULAR MATURATION, HIGH RESPONDERS, TRIGGER, HCG, COTREATMENT, INDUCTION, ESTRADIOL
  • Ankara Üniversitesi Adresli: Evet

Özet

Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles. (C) 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.